TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Expands its Specialty Medication Business by Opening Pharmacy Operations in California

The Oncology Institute Expands its Specialty Medication Business by Opening Pharmacy Operations in California

CERRITOS, Calif, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (TOI) announced today that it has started operations of its first pharmacy in California after receiving approval from the California State Board of Pharmacy. This new service allows TOI to fill not only critical specialty medications and chemotherapeutics for MediCal patients, but also to provide medication fill capabilities to other patient populations. Located in the Los Angeles area, this new pharmacy location comes in addition to the multiple integrated specialty medication dispensaries that TOI already uses to manage oral and injectable medications.

“We are ecstatic that we finally have the opportunity to significantly expand our oral drug business with this new pharmacy location,” shared Chief Executive Officer, Dr. Daniel Virnich. “We are seeking to address the cancer care costs of hundreds of thousands of MediCal patients that we were unable to serve through our dispensaries. Now, we expect to be able to fill their medications more quickly and conveniently.”

“TOI has proudly lowered out-of-pocket costs for patients that fill through our medically integrated dispensaries. We expect this to continue as we begin operations at our first pharmacy location,” commented Jessica Yankus, TOI’s National Vice President of Pharmacy. “This is an incredible service for both our patients and payor partners, so we anticipate similar opportunities to emerge in other states where we deliver care.”

About TOI

Founded in 2007, The Oncology Institute, Inc. (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit .

Contacts

Investors

Solebury Strategic Communications



EN
04/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute set to join the Russell 2000® and Russell 3000®...

The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by...

 PRESS RELEASE

The Oncology Institute Reports First Quarter 2025 Financial Results an...

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in th...

 PRESS RELEASE

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Off...

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Direct...

 PRESS RELEASE

The Oncology Institute to Participate at the B. Riley Securities 25th ...

The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering...

 PRESS RELEASE

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on H...

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch